Actively Recruiting
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Led by Centre Paul Strauss · Updated on 2026-02-04
54
Participants Needed
2
Research Sites
130 weeks
Total Duration
On this page
Sponsors
C
Centre Paul Strauss
Lead Sponsor
C
Centre Georges François Leclerc
Collaborating Sponsor
AI-Summary
What this Trial Is About
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
CONDITIONS
Official Title
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Glioblastoma, World Health Organization (WHO) grade IV, histologically proven
- Performance status 0, 1 or 2
- Neurological status 2 2
- Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)
- Radiological proven recurrence according to 1 and 2 criteria, Wen et al
- Remaining node after partial surgery post-recurrence
- 1 to 3 recurrence site(s) < 35 mm in wide axis and separated by at least 5 mm
- Volume of each lesion < 35 mL
- Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk > 10 mm
You will not qualify if you...
- Patient with contraindication to MRI or PET
- Glioblastomatose
- Pregnancy or breastfeeding
- Patient that do not understand French
- Patient without affiliation to the national or local social security
- Patients not able to comply to the protocol assessments for geographic, social or psychological reasons
- Minor or patients placed under guardianship or supervision
- Patients deprived of liberty
- Patients placed under judicial protection
- Patients that are not able to express their consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHRU de Nancy
Nancy, De, France, 5400
Not Yet Recruiting
2
Centre Paul Strauss
Strasbourg, France, 67033
Actively Recruiting
Research Team
A
Anne ANTHONY
CONTACT
M
MANON VOEGELIN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here